Cell Therapeutics (NASDAQ:CTIC) shares are getting a boost today after the company announced that a second independent radiology assessment of data from a clinical trial of the company's antitumor treatment pixantrone confirmed the statistical robustness of the data.
The response and progression endpoint data was previously submitted to the U.S. Food and Drug Administration with the new drug application for pixantrone.
The second assessment was recommended by the FDA's Office of New Drugs as part of Cell Therapeutic's appeal to the complete response letter it had previously received from the FDA.
The company said it plans on resubmitting the drug as early as next month for accelerated approval, which could provide an FDA action date by April 2012.
Cell Therapeutics had announced earlier in the week that a UnitedHealth Group (NYSE:UNH) executive, Reed Tuckson, has joined its board.
This year, the company has licensed rights from Chroma Therapeutics to develop tosedostat, and it has an ongoing relationship with Novartis (NYSE:NVS) for the licensing of Opaxio.
Any ideas and opinions presented in all Market News Video clips are for informational and educational purposes
only, and do not reflect the opinions of BNK Invest, Inc. or any of its affiliates, subsidiaries or partners.
In no way should any content contained herein be interpreted to represent trading or investment advice.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. Read Full Disclaimer.